The landscape of modern precision medicine is increasingly reliant on the accuracy and integrity of molecular diagnostics. At the forefront…
Read More
Bio-Techne Corporation Expands Global Cell Therapy Capabilities With New GMP Small Molecule Manufacturing Facility in Bristol
Life science tools and diagnostics provider Bio-Techne Corporation has officially opened a state-of-the-art, purpose-built manufacturing facility in Bristol, United Kingdom,…
Read More
Viatris Expands Into Non-Opioid Pain Market With $1.65bn Acquisition of Pacira BioSciences
The global pharmaceutical landscape is undergoing a profound structural shift as healthcare enterprises aggressively pivot away from traditional opioid-based narcotics…
Read More
Eli Lilly Expands Multi-Million Dollar Biotech Partnership with Gate Bioscience to Pioneer ‘Molecular Gate’ Therapies for Hard-to-Drug Proteins
Eli Lilly and Company has significantly deepened its footprint in cutting-edge drug discovery by expanding its strategic partnership and licensing…
Read More
Shionogi Expands Rare Disease Portfolio With $2 Billion Acquisition of IntraBio and Flagship Drug Aqneursa
Japanese pharmaceutical major Shionogi has announced a definitive agreement to acquire IntraBio in a multibillion-dollar transaction valued at $2 billion.…
Read More
FDA issues final PDUFA meeting guidance, expands use of written responses
The U.S. Food and Drug Administration (FDA) has officially finalized its long-awaited guidance regarding formal meetings between the agency and…
Read More
FDA Expands Approval of Bristol Myers Squibb’s Camzyos to Treat Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
The United States Food and Drug Administration (FDA) has officially expanded the approved indication for Bristol Myers Squibb’s (BMS) flagship…
Read More
Piramal Pharma Solutions Expands Global Footprint and Highlights Integrated Capabilities at CPHI Milan 2026
Piramal Pharma Solutions (PPS), a globally recognized contract development and manufacturing organization (CDMO), is preparing to exhibit its comprehensive suite…
Read More
Novo Nordisk Expands Cardiometabolic Portfolio With $2.3bn Hengrui Licensing Deal for Once-Weekly Oral GLP-1/GIP Agonist HRS-1596
In a strategic move to cement its leadership in the booming cardiometabolic therapeutics market, Danish pharmaceutical titan Novo Nordisk has…
Read More
FDA issues final PDUFA meeting guidance, expands use of written responses
The U.S. Food and Drug Administration (FDA) has officially finalized its long-awaited guidance regarding formal meetings between the agency and…
Read More
